Sonnet Biotherapeutics Holdings Inc
SONN1.260USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.20MMarket Cap
LossP/E TTM
More Details of Sonnet Biotherapeutics Holdings Inc Company
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Sonnet Biotherapeutics Holdings Inc Info
Ticker SymbolSONN
Company nameSonnet Biotherapeutics Holdings Inc
IPO dateJul 27, 2005
CEORao (Raghu)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJul 27
Address100 Overlook Center
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16093752227
Websitehttps://www.sonnetbio.com/
Ticker SymbolSONN
IPO dateJul 27, 2005
CEORao (Raghu)
Company Executives of Sonnet Biotherapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raghu Rao
Mr. Raghu Rao
Chief Executive Officer, Director
Chief Executive Officer, Director
2.36K
--
Mr. Jenene Thomas
Mr. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raghu Rao
Mr. Raghu Rao
Chief Executive Officer, Director
Chief Executive Officer, Director
2.36K
--
Mr. Jenene Thomas
Mr. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Republic Digital Opportunistic Digital Assets Master Fund Ltd
3.67%
Ikarian Capital LLC
2.12%
The Vanguard Group, Inc.
1.36%
Kenney (Richard T)
1.11%
HRT Financial LP
1.05%
Other
90.69%
Shareholders
Shareholders
Proportion
Republic Digital Opportunistic Digital Assets Master Fund Ltd
3.67%
Ikarian Capital LLC
2.12%
The Vanguard Group, Inc.
1.36%
Kenney (Richard T)
1.11%
HRT Financial LP
1.05%
Other
90.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.75%
Corporation
3.67%
Hedge Fund
3.00%
Investment Advisor/Hedge Fund
2.24%
Research Firm
2.01%
Individual Investor
1.22%
Other
84.11%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
29
348.20K
4.92%
-443.97K
2025Q2
42
217.03K
3.73%
-164.88K
2025Q1
49
216.94K
6.86%
-38.71K
2024Q4
47
142.46K
4.65%
-26.07K
2024Q3
47
41.15K
2.68%
-136.57K
2024Q2
52
111.48K
15.39%
+15.28K
2024Q1
53
47.27K
6.49%
-61.26K
2023Q4
55
63.31K
18.25%
-49.43K
2023Q3
54
43.80K
20.23%
-50.04K
2023Q2
52
54.80K
26.54%
-1.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Republic Digital Opportunistic Digital Assets Master Fund Ltd
260.00K
3.81%
+260.00K
--
Jul 14, 2025
The Vanguard Group, Inc.
28.10K
0.41%
--
--
Aug 31, 2025
Kenney (Richard T)
1.37K
0.02%
--
--
Aug 26, 2025
Geode Capital Management, L.L.C.
24.89K
0.36%
+87.00
+0.35%
Jun 30, 2025
BIT Capital GmbH
428.79K
6.28%
+234.14K
+120.28%
Aug 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Date
Type
Ratio
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Sep 16, 2022
Merger
14→1
Sep 16, 2022
Merger
14→1
View more
FAQs
Who are the top five shareholders of Sonnet Biotherapeutics Holdings Inc?
The top five shareholders of Sonnet Biotherapeutics Holdings Inc are:
Republic Digital Opportunistic Digital Assets Master Fund Ltd holds 260.00K shares, accounting for 3.81% of the total shares.
The Vanguard Group, Inc. holds 28.10K shares, accounting for 0.41% of the total shares.
Kenney (Richard T) holds 1.37K shares, accounting for 0.02% of the total shares.
Geode Capital Management, L.L.C. holds 24.89K shares, accounting for 0.36% of the total shares.
BIT Capital GmbH holds 428.79K shares, accounting for 6.28% of the total shares.
Republic Digital Opportunistic Digital Assets Master Fund Ltd holds 260.00K shares, accounting for 3.81% of the total shares.
The Vanguard Group, Inc. holds 28.10K shares, accounting for 0.41% of the total shares.
Kenney (Richard T) holds 1.37K shares, accounting for 0.02% of the total shares.
Geode Capital Management, L.L.C. holds 24.89K shares, accounting for 0.36% of the total shares.
BIT Capital GmbH holds 428.79K shares, accounting for 6.28% of the total shares.
What are the top three shareholder types of Sonnet Biotherapeutics Holdings Inc?
The top three shareholder types of Sonnet Biotherapeutics Holdings Inc are:
Republic Digital Opportunistic Digital Assets Master Fund Ltd
Ikarian Capital LLC
The Vanguard Group, Inc.
Republic Digital Opportunistic Digital Assets Master Fund Ltd
Ikarian Capital LLC
The Vanguard Group, Inc.
How many institutions hold shares of Sonnet Biotherapeutics Holdings Inc (SONN)?
As of 2025Q3, 29 institutions hold shares of Sonnet Biotherapeutics Holdings Inc, with a combined market value of approximately 348.20K, accounting for 4.92% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.19%.
What is the biggest source of revenue for Sonnet Biotherapeutics Holdings Inc?
In --, the -- business generated the highest revenue for Sonnet Biotherapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
